This is the authors' abstract. We don't add key points for this paper.
PURPOSE: At-labeled α-MSH peptide analog for TAT of metastatic melanoma. METHODS: At]NpG-GGN4c (1 or 0.4 MBq). RESULTS: At]NpG-GGN4c exhibited a dose-dependent inhibitory effect on B16F10 xenograft growth without apparent body weight loss. CONCLUSION: At]NpG-GGN4c is a promising TAT agent for treating metastatic melanoma.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: